Caitlin Elizabeth Kalinowski Sells 564 Shares of Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise, Inc (NASDAQ:AXONGet Free Report) Director Caitlin Elizabeth Kalinowski sold 564 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $478.97, for a total transaction of $270,139.08. Following the completion of the sale, the director owned 3,632 shares of the company’s stock, valued at approximately $1,739,619.04. This trade represents a 13.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Axon Enterprise Trading Down 1.8%

NASDAQ:AXON opened at $481.48 on Thursday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. The firm has a market cap of $38.81 billion, a price-to-earnings ratio of 193.37, a price-to-earnings-growth ratio of 8.91 and a beta of 1.45. Axon Enterprise, Inc has a 52 week low of $339.01 and a 52 week high of $885.91. The firm has a 50-day moving average price of $406.39 and a two-hundred day moving average price of $492.25.

Axon Enterprise (NASDAQ:AXONGet Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, beating the consensus estimate of $1.60 by $0.01. The firm had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company’s revenue for the quarter was up 33.7% on a year-over-year basis. During the same quarter last year, the business posted $1.47 EPS. On average, equities analysts expect that Axon Enterprise, Inc will post 1.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Axon Enterprise

Large investors have recently modified their holdings of the stock. NEOS Investment Management LLC grew its stake in Axon Enterprise by 82.7% in the 3rd quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock valued at $18,206,000 after buying an additional 11,482 shares in the last quarter. Legal & General Group Plc grew its stake in Axon Enterprise by 1.3% in the 4th quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock valued at $242,241,000 after buying an additional 5,419 shares in the last quarter. Vanguard Group Inc. grew its stake in Axon Enterprise by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after buying an additional 376,904 shares in the last quarter. Eurizon Capital SGR S.p.A. purchased a new position in Axon Enterprise in the 4th quarter valued at approximately $13,116,000. Finally, Wealth Enhancement Advisory Services LLC grew its stake in Axon Enterprise by 93.1% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 23,365 shares of the biotechnology company’s stock valued at $13,270,000 after buying an additional 11,262 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on AXON shares. UBS Group decreased their price objective on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. Weiss Ratings upgraded shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Zacks Research upgraded shares of Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Piper Sandler decreased their price target on shares of Axon Enterprise from $690.00 to $674.00 and set an “overweight” rating for the company in a research note on Thursday, May 7th. Finally, Needham & Company LLC decreased their price target on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, February 20th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $712.75.

View Our Latest Analysis on AXON

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

About Axon Enterprise

(Get Free Report)

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

See Also

Insider Buying and Selling by Quarter for Axon Enterprise (NASDAQ:AXON)

Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.